Quick Answer
Spero Therapeutics, Inc. reported Total Assets of $68.92 million for the year ending 2025.
- Spero Therapeutics, Inc. showed a decrease of -37.7% in Total Assets from 2024 to 2025.
- This data is from Spero Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $31.55 million | Q1 2018: $81.06 million | Q2 2018: $72.59 million | Q3 2018: $136.12 million | Q1 2019: $124.65 million | Q2 2019: $122.49 million | Q3 2019: $112.51 million | Q1 2020: $109.89 million | Q2 2020: $97.55 million | Q3 2020: $157.04 million | Q1 2021: $143.44 million | Q2 2021: $119.59 million | Q3 2021: $144.69 million | Q1 2022: $145.83 million | Q2 2022: $63.63 million | Q3 2022: $64.48 million | Q1 2023: $112.55 million | Q2 2023: $98.89 million | Q3 2023: $107.10 million | Q1 2024: $167.70 million | Q2 2024: $149.88 million | Q3 2024: $135.16 million | Q1 2025: $77.71 million | Q2 2025: $62.12 million | Q3 2025: $54.17 million.
- Over the full 10 years of available data (2016 to 2025), Spero Therapeutics, Inc.'s Total Assets has grown by 400.4%.
- Historical annual values: Fiscal year 2025: $68.92 million | Fiscal year 2024: $110.54 million | Fiscal year 2023: $182.39 million | Fiscal year 2022: $124.80 million | Fiscal year 2021: $171.07 million | Fiscal year 2020: $153.45 million | Fiscal year 2019: $106.10 million | Fiscal year 2018: $129.01 million | Fiscal year 2017: $93.48 million | Fiscal year 2016: $13.77 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: